These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 28188495)

  • 1. Cancer treatment and the KIR-HLA system: an overview.
    Leone P; De Re V; Vacca A; Dammacco F; Racanelli V
    Clin Exp Med; 2017 Nov; 17(4):419-429. PubMed ID: 28188495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA and KIR polymorphisms affect NK-cell anti-tumor activity.
    Passweg JR; Huard B; Tiercy JM; Roosnek E
    Trends Immunol; 2007 Oct; 28(10):437-41. PubMed ID: 17825623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of the immunogenetic KIR and HLA systems on long-term renal transplant outcome.
    La Manna G; Corsini S; Iannelli S; Cappuccilli ML; Comai G; Iorio M; Todeschini P; Carretta E; Scolari MP; Bontadini A; Stefoni S
    Ann Transplant; 2013 Nov; 18():611-21. PubMed ID: 24220609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KIR and HLA under pressure: evidences of coevolution across worldwide populations.
    Augusto DG; Petzl-Erler ML
    Hum Genet; 2015 Sep; 134(9):929-40. PubMed ID: 26099314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of KIR and HLA interactions in pregnancy complications.
    Colucci F
    Immunogenetics; 2017 Aug; 69(8-9):557-565. PubMed ID: 28695287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.
    Bernson E; Hallner A; Sander FE; Wilsson O; Werlenius O; Rydström A; Kiffin R; Brune M; Foà R; Aurelius J; Martner A; Hellstrand K; Thorén FB
    Leukemia; 2017 Dec; 31(12):2552-2559. PubMed ID: 28529313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NK cell killer Ig-like receptor repertoire acquisition and maturation are strongly modulated by HLA class I molecules.
    Sleiman M; Brons NH; Kaoma T; Dogu F; Villa-Forte A; Lenoble P; Hentges F; Kotsch K; Gadola SD; Vilches C; Zimmer J
    J Immunol; 2014 Mar; 192(6):2602-10. PubMed ID: 24554773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of the killer cell immunoglobulin-like receptor system.
    Rajalingam R
    Methods Mol Biol; 2012; 882():391-414. PubMed ID: 22665247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activating KIR molecules and their cognate ligands prevail in children with a diagnosis of ASD and in their mothers.
    Guerini FR; Bolognesi E; Chiappedi M; Manca S; Ghezzo A; Agliardi C; Zanette M; Littera R; Carcassi C; Sotgiu S; Clerici M
    Brain Behav Immun; 2014 Feb; 36():54-60. PubMed ID: 24120931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Killer cell immunoglobulin-like receptor gene diversity in a Southern Brazilian population from the state of Paraná.
    Rudnick CC; Franceschi DS; Marangon AV; Guelsin GA; Sell AM; Visentainer JE
    Hum Immunol; 2008 Dec; 69(12):872-6. PubMed ID: 18848853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Influence of donor activating or inhibitory KIR on prognosis of unmanipulated allogeneic hematopoietic stem cell transplantation].
    Liang ZY; Ren HY; Cen XN; Qiu ZX; Wang LH; Ou JP; Li Y; Wang MJ; Wang WS; Xu WL; Dong YJ; Yin Y; Sun YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):155-60. PubMed ID: 23484711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging role for the killer-cell immunoglobulin-like receptors genotype, in the susceptibility of skin diseases.
    Matusiak Ł; Białynicki-Birula R; Szepietowski JC
    J Dermatol Sci; 2013 Jul; 71(1):3-11. PubMed ID: 23642663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA and killer immunoglobulin-like receptor genes as outcome predictors of hepatitis C virus-related hepatocellular carcinoma.
    Cariani E; Pilli M; Zerbini A; Rota C; Olivani A; Zanelli P; Zanetti A; Trenti T; Ferrari C; Missale G
    Clin Cancer Res; 2013 Oct; 19(19):5465-73. PubMed ID: 23938290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of Killer cell immunoglobulin like receptor genes in end stage renal disease among North Indian population.
    Prakash S; Alam S; Sharma RK; Sonawane A; Imran M; Agrawal S
    Hum Immunol; 2013 Oct; 74(10):1339-45. PubMed ID: 23777934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings.
    Clausen J; Kircher B; Auberger J; Schumacher P; Ulmer H; Hetzenauer G; Wolf D; Gastl G; Nachbaur D
    Biol Blood Marrow Transplant; 2010 Feb; 16(2):273-80. PubMed ID: 19857587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Influence of HLA and KIR Genes on Malignant Melanoma Development and Progression.
    Kandilarova SM; Paschen A; Mihaylova A; Ivanova M; Schadendorf D; Naumova E
    Arch Immunol Ther Exp (Warsz); 2016 Dec; 64(Suppl 1):73-81. PubMed ID: 28083606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Killer cell immunoglobulin-like receptors influence the innate and adaptive immune responses.
    Rajalingam R
    Iran J Immunol; 2007 Jun; 4(2):61-78. PubMed ID: 17652846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity.
    Terszowski G; Klein C; Stern M
    J Immunol; 2014 Jun; 192(12):5618-24. PubMed ID: 24795454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KIRs and their HLA ligands in remitting-relapsing multiple sclerosis.
    Fusco C; Guerini FR; Nocera G; Ventrella G; Caputo D; Valentino MA; Agliardi C; Gallotti J; Morra VB; Florio C; Clerici M; Lombardi ML
    J Neuroimmunol; 2010 Dec; 229(1-2):232-7. PubMed ID: 20826009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.